A Phase II, Single-arm, Multicenter, Prospective Study of Cardunolizumab in Recurrent or Metastatic Vulvar and Vaginal Cancer
To evaluate the efficacy and safety of cardunolizumab in combination with/without chemotherapy ± bevacizumab for recurrent or metastatic vulvar and vaginal cancers that are not amenable to radical treatment.
Vulvar and Vaginal Cancer
DRUG: Cardunolizumab
Objective Response Rate (ORR), ORR is defined as the proportion of subjects with confirmed CR or PR, based on RECIST v1.1., Up to 2 years
Progression-free survival (PFS), PFS is defined as the time from the start of treatment with Cardunolizumab until the first documentation of disease progression or death due to any cause, whichever occurs first., Up to 2 years|Overall survival (OS), OS is defined as the time from the start of treatment with Cardunolizumab until death due to any cause., Up to 2 years|Disease control rate (DCR), DCR is defined as the proportion of subjects with confirmed CR, PR, or SD, based on RECIST v1.1., Up to 2 years|Duration of response (DOR), DOR is defined as the duration from the first documentation of objective response to the first documented disease progression or death due to any cause, whichever occurs first., Up to 2 years|Adverse events (AEs), Incidences of treatment-emergent adverse events (TEAEs) , treatment-related adverse events (TRAEs) as assessed by CTCAE v5.0, From first dose of Cardunolizumab through to 90 days after last dose of Cardunolizumab
To evaluate the efficacy and safety of cardunolizumab in combination with/without chemotherapy ± bevacizumab for recurrent or metastatic vulvar and vaginal cancers that are not amenable to radical treatment.